Patients with psoriatic arthritis and other inflammatory joint diseases have a high risk of cardiovascular disease (CVD), but use relatively little preventive medication such as antihypertensive and lipid lowering agents. An unmet need exists for the optimization of CVD prevention in this high-risk patient population.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Agca, R. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann. Rheum. Dis. 76, 17–28 (2017).
Eder, L. et al. Gaps in diagnosis and treatment of cardiovascular risk factors in patients with psoriatic disease: an international multicenter study. J. Rheumatol. 45, 378–384 (2018).
Wibetoe, G. et al. Cardiovascular disease risk profiles in inflammatory joint disease entities. Arthritis Res. Ther. 19, 153 (2017).
Gulati, A. M. et al. On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trondelag health study. Ann. Rheum. Dis. 75, 819–824 (2016).
Eder, L. et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J. Rheumatol. 35, 877–882 (2008).
Piepoli, M. F. et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Eur. Heart J. 37, 2315–2381 (2016).
Semb, A. G. et al. Exploring cardiovascular disease risk evaluation in patients with inflammatory joint diseases. Int. J. Cardiol. 223, 331–336 (2016).
Eder, L., Chandran, V. & Gladman, D. D. The Framingham risk score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann. Rheum. Dis. 73, 1990–1996 (2014).
Kotseva, K. et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur. J. Prev. Cardiol. 23, 636–648 (2016).
de Jong, M. J. et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet 390, 959–968 (2017).
Acknowledgements
The work of the authors is supported financially by grants from the South-Eastern Regional Health Authority of Norway (grant numbers 2013064 and 2016063).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interest
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Semb, A.G., Rollefstad, S. Optimization of CVD prevention in psoriatic arthritis. Nat Rev Rheumatol 14, 323–324 (2018). https://doi.org/10.1038/s41584-018-0002-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-018-0002-z
